Fichas
HPA - metaprolol (main drug)
Fichas del conjunto (11)
- 1Target receptorsBeta1 adrenergic receptors (competitively binds, blocking norepinephrine) - g protein coupled receptor
- 2Trade namesBetaloc, Lopresor, Metatar, Metrol, Metoprolol
- 3Therapeutic classAntianginal and Antihypertensive
- 4Pharmacological classSelective beta1 blocker
- 5Indications● Mild to severe hypertension
● Angina pectoris
● Myocardial infarction
● Cardiac arrythmias
● Heart failure - 6ActionCompetitively inhibit beta-adrenoceptors (sympathetic nervous system), thereby reducing some of the body’s response to adrenaline (epinephrine), noradrenaline and isoprenaline
- 7Therapeutic effects● Decreased BP and heart rate.
● Decreased frequency of attacks of angina pectoris.
Decreased rate of cardiovascular mortality and hospitalization in patients with heart failure. - 8Contraindications/precautionsIndividuals hypersensitive to drug or other beta blockers.
Sinus bradycardia, heart block greater than first degree, cardiogenic shock or overt cardiac failure
When used to treat MI, individuals with heart rate less than 45 beats per minute, second or third-degree heart block, systolic blood pressure less than 100mmHg or moderate to severe cardiac failure - 9Adverse reactionsCNS: fatigue, dizziness, depression CV: bradycardia, hypotension, heart failure, AV block GI: nausea, diarrhoea Respiratory: dyspnoea, bronchospasm Skin: rash
- 10AssessmentsBP
HR
Cardiac
Monitor for effectiveness - 11Patient educationInstruct patient to take drug at meals and to keep taking it exactly as prescribed.
Advise not to stop drug suddenly but to notify prescriber if unpleasant adverse reactions occur.
Emphasize that drug must be withdrawn gradually over 1 to 2 weeks
Información
- Descripción
- El usuario ha eliminado su información de asignaturas Fichas sobre HPA - metaprolol (main drug) , creado por Usuario eliminado el 10/06/2018.
- Creado por
- Usuario eliminado · jun 2018
- Actualizado
- 10 jun 2018
- Visitas
- 9
- Historial
-
- Creado por Em J · 10 jun 2018
- Copiado por Em J · 10 jun 2018
- Valoración